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In Brief
Chappell et al. present structures of the
T-cell surface receptor, CD6, the first of
consecutive scavenger receptor cysteine
rich domains and its ligand, CD166. The
structures give insight into how CD6 and
its interactions are perturbed by
competition between homophilic and
heterophilic interactions, SNPs, and
mAbs.
Structure
ArticleStructures of CD6 and Its Ligand CD166
Give Insight into Their Interaction
Paul E. Chappell,1 Lee I. Garner,1 Jun Yan,2 Clive Metcalfe,1 Deborah Hatherley,1 Steven Johnson,1 Carol V. Robinson,2
Susan M. Lea,1 and Marion H. Brown1,*
1Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK
2Department of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, South Parks Road, Oxford OX1 3RE, UK
*Correspondence: marion.brown@path.ox.ac.uk
http://dx.doi.org/10.1016/j.str.2015.05.019
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARY
CD6 is a transmembrane protein with an extracellular
region containing three scavenger receptor cysteine
rich (SRCR) domains. The membrane proximal
domain of CD6 binds the N-terminal immunoglobulin
superfamily (IgSF) domain of another cell surface
receptor, CD166, which also engages in homophilic
interactions. CD6 expression is mainly restricted
to T cells, and the interaction between CD6 and
CD166 regulates T-cell activation. We have solved
the X-ray crystal structures of the three SRCR
domains of CD6 and two N-terminal domains of
CD166. This first structure of consecutive SRCR
domains reveals a nonlinear organization. We char-
acterized the binding sites on CD6 and CD166 and
showed that a SNP in CD6 causes glycosylation
that hinders the CD6/CD166 interaction. Native
mass spectrometry analysis showed that there is
competition between the heterophilic and homo-
philic interactions. These data give insight into how
interactions of consecutive SRCR domains are per-
turbed by SNPs and potential therapeutic reagents.
INTRODUCTION
CD6 is a lymphocyte membrane receptor characterized as being
primarily expressed on T cells and someB cells. The extracellular
region of CD6 contains three scavenger receptor cysteine rich
(SRCR) domains and a membrane proximal stalk (Figure 1).
CD6 engages in cell-cell interactions by binding to the immuno-
globulin superfamily (IgSF) cell surface receptor, CD166, other-
wise known as activated leukocyte adhesion molecule (ALCAM)
(Aruffo et al., 1997; Bowen et al., 1995) (Figure 1). CD166 is ex-
pressed more widely than CD6 and is found on both hematopoi-
etic and nonhematopoietic cells (Chitteti et al., 2013). In this trans
interaction between cells, themembrane proximal SRCRdomain
ofCD6binds theN-terminal domainofCD166 (Aruffo et al., 1997).
In addition to heterophilic interactions with CD6, CD166 also
engages in homophilic interactions in trans between apposing
cells (Te Riet et al., 2007; van Kempen et al., 2001) (Figure 1).
As in binding CD6, homophilic interactions of CD166 depend
on the N-terminal domain (Bowen et al., 1996; van Kempen1426 Structure 23, 1426–1436, August 4, 2015 ª2015 The Authorset al., 2001). Although weaker than the heterophilic CD6/
CD166 interaction (Hassan et al., 2004; Te Riet et al., 2007),
CD166 homophilic interactions have pleiotropic effects and
regulate not only normal but also neoplastic cells (Chitteti
et al., 2013; Weidle et al., 2010). Soluble fusion proteins of the
extracellular regions of CD6 or CD166 inhibit T-cell responses
(Gimferrer et al., 2004; Hassan et al., 2004; Zimmerman et al.,
2006). A CD6 monoclonal antibody (mAb) against domain 3,
characterized biochemically as blocking CD6/CD166 interac-
tions distinguished between effects of heterophilic CD6/CD166
and homophilic CD166/CD166 interactions (Hassan et al.,
2006). This mAb inhibited antigen-specific proliferation in a poly-
clonal population of human blood cells, revealing a costimulatory
role for engagement of CD6 by CD166 (Hassan et al., 2006).
The inhibitory effect of blocking extracellular engagement of
CD6 and CD166 identifies these receptors as potential therapeu-
tic targets for immunosuppression.
Costimulation by CD6 is dependent on phosphorylation of a
C-terminal tyrosine motif which is specific for the adaptor pro-
tein, SLP-76 (Hassan et al., 2006). CD6 has an extraordinarily
long cytoplasmic tail (244 amino acids) and provides an alterna-
tive to LAT as a scaffold for assemblies of signaling proteins in
T cells (Roncagalli et al., 2014). In contrast, CD166 has a short
cytoplasmic region that regulates adhesion through a link with
the cytoskeleton (Te Riet et al., 2014). Expression of CD6 raises
the threshold of activation, and overall net inhibitory or costimu-
latory effects depend on the particular immune response being
measured (Hassan et al., 2006; Oliveira et al., 2012). The dual ef-
fects of CD6 make it difficult to interpret the consequences of
SNPs that alter the expression of CD6 and correlatewith suscep-
tibility to multiple sclerosis (De Jager et al., 2009; Heap et al.,
2010; Kofler et al., 2011; Swaminathan et al., 2013).
It is not yet clear how themultiple domains ofCD6are important
for function. In theabsenceofdomain3, no interactionwithCD166
can be detected biochemically (Bowen et al., 1996; Hassan et al.,
2004). However, CD6 domain 1 mAbs are inhibitory in cellular as-
says (Kofler et al., 2011; Nair et al., 2010; Singer et al., 1996; Zim-
merman et al., 2006), and one has been recently licensed in India
for use as an immunosuppressant for psoriasis (Jayaraman,
2013). Inhibition by a CD6 domain 1 mAb depends on the pres-
ence of CD6 domain 3, supporting the hypothesis that CD6
domain 1 mAbs perturb CD166/CD6 interactions between cells
by steric hindrance (Bowen et al., 1995; Kofler et al., 2011).
Consecutive domains are a feature of group Bmembers of the
SRCR domain superfamily (reviewed in Herzig et al., 2010) with
three consecutive group B SRCR domains found in the closely
Figure 1. Heterophilic and Homophilic Interactions of CD6 and
CD166 between Cells
CD6 contains three SRCR domains (Sc, squares) and CD166 contains five
IgSF domains (two V and three C2). The membrane proximal domain of CD6
binds the N-terminal immunoglobulin superfamily (IgSF) domain (oval) of
CD166.related cell surface proteins CD5 and CD6, and the soluble
Apoptosis Inhibitor of Macrophages (AIM), also known by other
names (Spa, CD5L), which comprises solely three consecutive
SRCR domains. The involvement of multiple consecutive
SRCR domains in ligand binding has been well characterized
for the leukocyte surface receptor CD163, the second and third
SRCR domains cooperating in ligand binding to hemoglobin/
haptoglobin complexes (Nielsen et al., 2013). All three SRCR
domains contribute to ligand binding by AIM (Spa, CD5L), which
was found to be associated with immunoglobulin M (IgM) in
serum (Arai et al., 2013; Tissot et al., 2002).
The crystal structure of CD6 is the first of consecutive SRCR
domains, earlier structures being of single SRCR domains
(Garza-Garcia et al., 2008; Hohenester et al., 1999; Rodamilans
et al., 2007). We reveal a nonlinear arrangement of the CD6
SRCR domains, which leads us to hypothesize about the roles
of the individual domains and their different interactions.
RESULTS
Purification, Characterization, and Crystallization
of CD6 and CD166
Recombinant His-tagged proteins of human CD6 SRCR do-
mains 1–3 and human CD166 IgSF domains 1–3, i.e. the twoN-terminal V domains and one C domain (CD166 VVC), were sta-
bly expressed in Lec 3.2.8.1 Chinese hamster ovary (CHO) cells
(Chen and Stanley, 2003), purified, and deglycosylated. Protein
crystals of the individual proteins were grown and diffraction
data collected. We confirmed that the proteins used in this study
interact as expected (data not shown and see Supplemental In-
formation) (Bowen et al., 2000; Hassan et al., 2004).
X-Ray Crystal Structure of CD6 Reveals a Nonlinear
Organization of Consecutive SRCR Domains
X-Ray diffraction data were collected to 3.15 A˚ and the structure
solved by molecular replacement using a search model derived
from the structure of a single SRCR domain of Mac-2
binding protein (PDB: 1BY2, 26.7% sequence identity to CD6
domain 1, 44.5% to CD6 domain 2, and 26.1% to CD6 domain
3; Hohenester et al., 1999) (Table 1). The X-ray structure of
CD6 is the first structure for a protein containing consecutive
SRCR domains (Figures 2A and 2B).
The structure reveals a nonlinear organization of consecutive
SRCR domains of CD6. Despite the interdomain interactions
not being conserved, the orientations of each domain relative
to its adjacent domain are very similar, both burying approxi-
mately 270 A˚2. A consequence of this orientation at the
interfaces between individual SRCR domains is a nonlinear
consecutive domain structure, resulting in the three domains
spanning 78.1 A˚, a shorter distance than if the domains were
in a linear arrangement (Figures 2A and 2B). This structural
feature was also observed in a lower resolution dataset
collected from a different crystal form (data not shown), sup-
porting the idea that this is a biologically relevant structural
feature. There is a disordered region in CD6 domain 1 in a
similar position to a flexible loop in CD5 domain 1 (Garza-Gar-
cia et al., 2008).
Mapping Domain 3 Mutants on the CD6 Structure
Identifies the Ligand Binding Site for CD166
Previous studies identified CD6 domain 3 and CD166 domain 1
as being sufficient to mediate ligand binding (Bowen et al.,
1996; Whitney et al., 1995). The role of the other two CD6
SRCR domains in the heterophilic interaction is not clear. We
quantified binding of soluble recombinant CD166 VVC to
different forms of streptavidin-immobilized chimeric CD6 by
surface plasmon resonance (SPR), in an attempt to detect
any contribution of CD6 domains 1 and 2. No difference was
detected in the binding of CD166 VVC to CD6, CD6 lacking
domain 1, or CD6 lacking domains 1 and 2 (Figure S1; Table S1).
Using our structure of CD6 and previous mutagenesis data
(Bodian et al., 1997; Skonier et al., 1997), we carried out a
more extensive mutagenesis study on CD6 domain 3 (Figures
2B and S2; Table S2; see Figure 4A) to define the residues crit-
ical for CD166 binding. These data were mapped onto the
structure, clearly identifying and defining the boundaries of
the surface of CD6 that interacts with CD166. There is a high
degree of amino acid conservation in this binding face between
human, mouse, and rat CD6 sequences (Figure 3). Within this
region amino acids have been identified that reduce binding
to CD166, so it is likely that different species use the same
face (Bowen et al., 2000) (Figure 3). We extended our previ-
ously published cross-species binding analysis to include ratStructure 23, 1426–1436, August 4, 2015 ª2015 The Authors 1427
Table 1. Crystallographic Data for CD6 and CD166
CD6 CD166
Data Collection
X-Ray source Diamond
Light Source,
beamline i04-1
Diamond
Light Source,
beamline i04-1
Wavelength (A˚) 0.92 0.92
Resolution range (A˚) 77.93–3.15
(3.23–3.15)
51.14–1.86
(1.91–1.86)
Space group P 63 2 2 P 43 21 2
Unit Cell
a, b, c (A˚) 161.48, 161.48, 93.85 72.32, 72.32, 105.04
a, b, g () 90, 90, 120 90, 90, 90
Total reflections 69,680 (5,176) 313,66 (22,938)
Unique reflections 12,884 (933) 24,110 (1,731)
Multiplicity 5.4 (5.5) 13.0 (13.3)
Completeness (%) 99.6 (99.8) 99.9 (99.9)
Mean I/s(I) 7.2 (2.2) 20.1 (3.8)
Rmerge (all I
+ and I) (%) 23.2 (80.0) 8.0 (65.9)
Refinement
Resolution range (A˚) 77.93–3.15 21.09–1.86
No. of reflections
(work/test set)
12,883/629 24,029/1,229
No. of atoms
(protein, glycans,
ligands, waters)
4,399, 27, 60, 43 3,496, 54, 160, 186
Protein residues 324 218
Mean B-factors
(protein, glycans,
ligands, waters) (A˚2)
37.85, 61.24, 35.33,
10.28
32.53, 47.28, 59.05,
38.80
Rwork (%) 25.31 22.17
Rfree (%) 28.31 23.91
Rmsd from ideal
values (bonds, A˚)
0.0061 0.0061
Rmsd from ideal
values (angles, )
0.76 0.93
Ramachandran plot
Favored regions (%) 95.05 96.79
Outliers (%) 0 0
Rmsd, root-mean-square deviation.CD6, and showed that human CD166 bound human, mouse,
and rat CD6 with the same affinity (Hassan et al., 2006 and
data not shown).
Mapping Domain 1 Mutants on the X-Ray Crystal
Structure of CD166 Identifies the Ligand Binding
Site for CD6
X-Ray diffraction data for crystals containing CD166 VVC were
collected to 1.86 A˚ and the structure solved by molecular
replacement with a search model derived from the second
IgSF domain of RAGE (PDB: 3CJJ, 16.4% sequence identity to
domain 1 and 30.3% to domain 2; Koch et al., 2010). Only the
first two domains could be resolved in the electron density
map (Figures 2C and 2D). The crystal lattice did not contain1428 Structure 23, 1426–1436, August 4, 2015 ª2015 The Authorsspace to accommodate the third domain, suggesting it had
been proteolytically cleaved prior to crystal growth.
We mapped previous mutagenesis data that defined residues
in CD166 domain 1 critical for CD6 binding (Skonier et al., 1996a,
1996b) onto the crystal structure (Figures 2D; Table S3; see Fig-
ure 4B). This confirmed the prediction that binding to CD6 is
mediated by the AGFCC0C00 face, in common with many other
IgSF interactions (Skonier et al., 1996a, 1996b). We repeated
mutagenesis of five of these residues in CD166 domain 1 and
confirmed that they all disrupted CD6/CD166 interactions (Fig-
ure S3; Table S3).
There Is Complementary Electrostatic Potential
between CD166 and CD6 Binding Sites
Mutagenesis of CD6 domain 3 (Bodian et al., 1997; Skonier et al.,
1997) (Table S2 and Figure 4A: N346K, N348R, Q352R) showed
that altering the charge from negative to positive in CD6 inhibited
CD166 binding. Conversely, altering the charge from positive to
negative in CD166 domain 1 (Table S3 and Figure 4B: K55E)
inhibited binding to CD6 (Skonier et al., 1996a, 1996b). Loss of
charged amino acids (Table S3 and Figure 4B: E118A, K75A,
D81A) in CD166 domain 1 also reduced binding, consistent
with electrostatic potential being important for ligand binding.
The calculated electrostatic potentials of the proposed interface
between CD6 and CD166 are compatible with their interaction.
The CD6 surface features a stripe of negative charge flanked
with positive charge, and the CD166 surface features a comple-
mentary positively charged stripe flanked by negative charge
(Figure 4).
Mapping Domain 1 mAb Epitopes on the CD6 Structure
Shows How Ligand Binding between Cells Might Be
Disrupted
Inhibition by CD6 domain 1 mAbs has only been observed be-
tween cells, suggesting that intermembrane dimensions are
important for their effects (Bowen et al., 1996, 1995). To gain
some insight from the CD6 structure as to how CD6 domain 1
mAbs might disrupt CD6/CD166 interactions, we mapped the
epitope of a CD6 domain 1 mAb, MT605, which has been shown
to inhibit immune responses between cells expressing CD6 and
CD166 (Kofler et al., 2011; Singer et al., 1996; Zimmerman et al.,
2006). To identify the epitope, we produced alanine mutants of a
number of surface-exposed residues in CD6 domain 1. Binding
of MT605 was abolished by R77A (Figure S4). Binding of another
CD6 domain 1 mAb, MEM-98, was unaffected by R77A but was
eliminated by E63A. MT605 was unaffected by E63A (Figure S4).
In the orientation shown in Figure 2, R77 lies at the top of CD6
domain 1. A large antibody binding in this position may prevent
the close approach between cell membranes needed for CD6/
CD166 engagement.
CD6 Nonsynonymous SNPs Associated with Multiple
Sclerosis which Alter Expression Are Buried
Of the SNPs identified in CD6, five alter amino acids in domains 2
and 3 (Figure 5). Homozygotes for two of these SNPs (R225W
and A257V) in domain 2 have been associated with susceptibility
to multiple sclerosis (Swaminathan et al., 2013). These two res-
idues are buried within the domain and may disrupt the domain
structure and stability of the molecule, explaining the correlation
Figure 2. Structures of CD6 and CD166 Identify a Binding Interface and Reveal a Nonlinear Arrangement of Domains in CD6
(A and C) Cartoon diagrams colored from blue at the N terminus to red at the C terminus.
(B and D) Surface representations, with mutations in CD6 affecting ligand binding colored red.
Similar interdomain orientations of CD6 domains result in an overall nonlinear organization. A disordered loop exists in the N-terminal domain of CD6. Binding of
CD6 domain 1 mAb MT605 was specifically reduced by R77A mutation (see Figure S4).between reduced expression and susceptibility to multiple
sclerosis.
The CD6 SNP, S351N, Results in Glycosylation that
Disrupts CD6/CD166 Interactions
Of the surface-exposed SNPs in CD6, the change from S351 to
S351N found in 10% of the genomes analyzed (http://www.
1000genomes.org) is the only residue close to the ligand binding
site. Wemutated CD6 S351 to S351N and compared the binding
of soluble CD166 VVC to the two variants by SPR. CD166 VVC
bound with a 10-fold weaker affinity to CD6 S351N compared
with CD6 S351 (Figure S5; Table S5). Analysis of the kinetics ofbinding showed an increase in the dissociation rate of CD6
S351N compared with CD6 S351 (Figure S5; Table S4).
As S351N introduces a consensus N-linked glycosylation site
(NQS), binding of CD166 may be sterically hindered by carbohy-
drate. There are seven consensus N-glycosylation sites in the
three extracellular domains of CD6. In the recombinant protein,
we observed electron density for GlcNAc attached to residue
N229 in the second domain. There was no observable electron
density for the other potential glycosylation sites in CD6. Mass
spectrometry was used to determine whether recombinant
CD6 S351N is glycosylated. As glycosylated peptides are not
identified by liquid chromatography-tandem mass spectrometryFigure 3. CD6 SRCR Domains, Residues
43–364, which Bind CD166 Are Conserved
Across Species
Human (UniProt: P30203), mouse (UniProt:
Q61003), and rat (UniProt: Q5FVU4) CD6 bind
human CD166 (Hassan et al., 2006 and data not
shown). Compared with CD6 SRCR domain 3,
which binds CD166, CD6 domains 1 and 2 have
more variation in amino acid sequence between
human, mouse, and rat CD6.
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Figure 4. Complementary Electrostatic
Potential between CD166 and CD6 Binding
Faces
Surface representations of human CD6 (A) and
human CD166 (B) displaying electrostatic potential
(negative charge in red and positive charge in blue)
and mutations that do not affect binding (green)
and that affect binding (red). Areas of comple-
mentary electrostatic potential are outlined with a
dotted line.due to the unknown mass of the N-linked carbohydrate,
we quantified the precursor ion intensity obtained from
extracted ion chromatograms of the FNNSNLCS351QSLAAR
and FNNSNLCN351QSLAAR tryptic peptides before and after
deglycosylation (Figure S6; Table S5). The S351 peptide was
not glycosylated (Figures S6A and S6B), whereas the ion inten-
sity of the S351N peptide was dependent on deglycosylation,
showing that it was glycosylated (Figures S6C and S6D). Consis-
tent with the interpretation that S351N disrupted ligand binding
by introducing a bulky carbohydrate moiety in proximity to the
CD166 binding site, the CD6 mutant S351A restored binding,
as measured by SPR (Figure S5; Table S5).
The glycosylation states of the other putative glycosylation
sites in CD6 were determined qualitatively from the mass spec-
trometry data by comparing the number of peptide spectral
matches of peptides containing each N-linked glycosylation
site before and after deglycosylationwith peptide-N-glycosidase
F, showing that N28, N49, N229, and N351 are glycosylated and
that N339 appears to be partially glycosylated (Table S5).
Heterodimers Are Formed at the Expense of CD6
and CD166 Homodimers
Homophilic and heterophilic interactions of CD166 are mediated
by the N-terminal domain. Mutations in the A0GFCC0C00 face,
which disrupt CD6/CD166 interactions (Figure 2), map to the
crystal contacts between the two N-terminal domains in the
CD166 structure (Figure 6) (Bowen et al., 2000).1430 Structure 23, 1426–1436, August 4, 2015 ª2015 The AuthorsIf the heterophilic and homophilic
binding sites overlap, as implied by
the CD166 crystal contacts, homophilic
CD166 interactions would be disrupted
by the formation of heterodimers with
CD6.We examined themolecular species
present when CD6 and CD166 were
mixed in comparison with the individual
components by native mass spec-
trometry. When CD6 and CD166 were
analyzed separately, we found that both
CD6 and CD166 were predominantly in
monomer-dimer equilibrium (Figures 7A
and 7B). When CD6 and CD166 were
mixed, there was an increase in the
relative abundance of heterodimers, a
corresponding decrease of the CD6
and CD166 monomers, and a complete
depletion of homodimers when compared
with the unmixed samples (Figure 7C).These data show that heterodimers are formed at the expense
of CD6 and CD166 homodimers. Due to the heterogeneity in
molecular masses caused by glycosylation, the collision voltage
on the mass spectrometer was increased to achieve more
accurate mass determination, and these experimentally calcu-
lated masses are shown in Table 2. The mass of the heterodimer
was confirmed by analysis of its composition by tandem mass
spectrometry (data not shown).
Comparison of the molecular species identified in native mass
spectrometry and multi-angled light scattering also revealed a
dynamic equilibrium between the different species (Figure S7).
DISCUSSION
The structures of CD6 and CD166 give insight into the hetero-
philic CD6/CD166 and homophilic CD166/CD166 interactions
and those of other proteins containing consecutive SRCR do-
mains. The structure of CD6 is the first for proteins containing
consecutive SRCR domains. One striking feature is the nonlinear
domain organization, which has implications for the topology
and orientations of interactions with individual domains.
The Role of Consecutive SRCR Domains in CD6/CD166
Interactions
The relatively high affinity trans interaction between CD6 and
CD166 on apposing cells is mediated by the CD6 membrane
proximal domain. The main contribution of the other two CD6
Figure 5. Nonsynonymous SNPs in CD6
Associated with Disease Are Not in the
CD166 Binding Site
SNPs are mapped on the structure of CD6 and
displayed as spheres.SRCR domains to the CD6/CD166 interactionmay be to regulate
accessibility of CD166 to the membrane proximal domain of
CD6, as formation of CD6/CD166 heterodimers involves compe-
tition with the homophilic CD166 interactions. Trans CD166 ho-
mophilic interactions were inhibited by preventing clustering in
cis on the cell surface with an antibody specific for the mem-
brane proximal domains of CD166 or by a dominant negative
mutant lacking the N-terminal domain (van Kempen et al.,
2001, 2004; Weidle et al., 2010). Weak interactions in cis
between the membrane proximal domains of CD166 at the cell
surface may enhance homophilic adhesion in trans (van Kempen
et al., 2001; Wu et al., 2011). The projection of CD6 domain 1,
which results from the nonlinear domain organization, may be
important for preventing clustering of CD166 at the cell surface,
and may provide an additional steric hindrance mechanism to
disrupt the CD166 trans homodimers between cells.
The topology of the CD6 SRCR domains shows how CD6
domain 1 mAbs might impede access of CD166 to the mem-
brane proximal domain of CD6 between cells (Bowen et al.,
1995; Kofler et al., 2011). Inhibition of the CD6/CD166 interaction
by CD6 domain 1 mAbs has only been observed between cells
and is likely to be dependent on the level of CD6/CD166 engage-
ment (Bowen et al., 1995; Castro et al., 2007; Kofler et al., 2011;
Singer et al., 1996; Zimmerman et al., 2006).
The main role of domain 2 of CD6 may be as a spacer to main-
tain the projection of CD6 domain 1. However, in the character-
ization of an interaction between the SRCR domains of the
closely related protein CD5 and the V region of the heavy chain
of immunoglobulin, first reported in rabbit, only the isolated
domain 2 of human CD5 was capable of binding the V region
of the heavy chain of human immunoglobulin (Pospisil et al.,
2000). CD5 differs in topology from CD6 in containing a pro-
line-rich linker between domains 1 and 2 that may be important
for accessibility to domain 2.
A subsidiary role for domains other than CD6 domain 3 and
CD166 domain 1 in CD6/CD166 interactions, which are belowStructure 23, 1426–143the detection limit of SPR analysis, cannot
be completely ruled out, as there are data
suggesting weak interactions of other
domains in high-avidity binding assays
(Bowen et al., 1996). In the context of
a lattice formation between cells (Weidle
et al., 2010), a very low-affinity interaction
may be productive (Wu et al., 2011).
CD6 domain 2 may be important for
divalent cation-dependent interactions
of CD6, as it contains a conserved
triacidic motif D187/D188/E253 (Nielsen
et al., 2013). CD6/CD166 interactions
occur in the absence of divalent cations
(Hassan et al., 2004; Patel et al., 1995;
L.I.G., unpublished data).Homodimers of CD166 and also CD6 were detected in native
mass spectrometry (Figure 7). When mixed, the main species
was heterodimers of CD6 and CD166. Based on data for CD5,
CD6 homodimers are more likely to form in cis on the same
cell surface (Bamberger et al., 2011; Brown and Lacey, 2010).
The nonlinear arrangement of the SRCR domains in CD6 is
compatible with individual domains engaging in interactions in
different orientations. If the angle of projection of CD6 from
the cell surface is as depicted in Figures 1 and 2, it places the
N-terminal domain in a position that could be important for
creating contacts on the same cell surface, including homophilic
interactions. Deletion of the N-terminal domain of CD6 resulted
in a protein that was not stable at the cell surface, whereas
CD6 containing domain 1 but lacking the membrane proximal
domain is expressed stably at the cell surface (Castro et al.,
2007; Kofler et al., 2011;M.H.B., unpublished data). Dimerization
of CD6 might be important for stabilization at the surface in the
absence of ligand binding, and ligand engagement by CD166
may be important for stabilizing CD6 monomers at the cell sur-
face to maintain immune responses (Zimmerman et al., 2006).
Heterophilic CD6/CD166 and Homophilic CD166/CD166
Interactions
In the competition between CD6 domain 3 and the N-terminal
domain of CD166, heterodimers are formed at the expense of
the weaker homophilic interactions of CD166 (Hassan et al.,
2004; Te Riet et al., 2007; and see above). Crystal contacts in
the CD166 structure suggest that the sites for heterophilic and
homophilic binding on CD166 domain 1 overlap (Figure 6). Alter-
natively, heterophilic and homophilic interactions may compete
through steric hindrance.
The structures of the interacting domains, the membrane
proximal domain of CD6, domain 3, and the N-terminal domain
of CD166 showed that mutants that disrupt binding to CD166
cluster together on the surface of CD6 (Bodian et al., 1997; Skon-
ier et al., 1997), identifying the binding face on domain 3.6, August 4, 2015 ª2015 The Authors 1431
Figure 6. Crystal Contacts Identify a Potential CD166 Domain 1 Homophilic Binding Face
Cartoon representations colored from blue at the N-terminus to red at the C-terminus (A) and surface representations (B) of CD166 domains 1 and 2, showing a
binding interface between the A0GFCC0C00 faces (Bowen et al., 2000). The homophilic interface is outlined in black (C).Complementary mapping of mutants of CD166 that affected
ligand binding delineated the binding site predicted to be on
the A0GFCC0C00 face of the CD166 structure (Bodian et al.,
1997; Skonier et al., 1997).
The binding faces of CD6 SRCR domain 3 and CD166
domain 1 are predominantly positively and negatively charged,
respectively (Figure 4) (Bowen et al., 2000). Ligand binding by
SRCR domains in MARCO and CD163, in groups A and B,
respectively, involves complementarity in charge (Nielsen
et al., 2013; Ojala et al., 2007). Electrostatic potential is likely to
be important in the CD6/CD166 interaction.
Implications for Other Proteins Containing Consecutive
SRCR Domains
The interaction between CD6 and CD166 functions in the adap-
tive immune system, whereas the majority of SRCR superfamily
domains are found in the innate immune system (Herzig et al.,
2010). Preservation of the three consecutive SRCR domains
may be important for maintaining more promiscuous low-affinity
interactions (Abdi et al., 2014; Arai et al., 2013) with ligand bind-
ing depending on avidity with contributions from each domain,
as has been observed in the interaction between AIM (Spa,
CD5L) and IgM (Arai et al., 2013). There may be a similar
nonlinear domain arrangement in other proteins containing
consecutive SRCR domains that is important for multiple do-
mains making contact with a ligand. Modeling the conformation
of longer arrays of SRCR domains with similar length linker
sequences suggests that these proteins would form a helical
structure.
Group A SRCR domains containing proteins that consist of
polypeptides with single SRCR domains trimerize, which may
create an alternative topology for multivalent binding. There is
a model based on a crystal structure for how membrane distal
single SRCR domains of MARCO multimerize to form a large
ligand binding face for pathogens (Ojala et al., 2007). Direct path-
ogen binding has been described for several SRCR domains,
including CD6 (Sarrias et al., 2007). A bacterial binding peptide
motif was first identified in an SRCR domain of DMBT1, other-
wise known as salivary agglutinin (Bikker et al., 2004; Madsen
et al., 2010). A consensus sequence for this bacterial binding
peptide is found in CD6 SRCR domain 2 (Bikker et al., 2004).1432 Structure 23, 1426–1436, August 4, 2015 ª2015 The AuthorsExamining the position of this peptide on the structure of CD6,
the region is predominantly surface exposed and is on the oppo-
site face to the CD166 binding site. Its significance is uncertain.
Mutation of this consensus sequence in the SRCR domain pro-
tein WC1 did not affect bacterial binding (Hsu et al., 2015).
Effects of Single Polymorphisms in CD6
Selection pressure for nonsynonymous SNPs in CD6 domain 2
that are associated with susceptibility to multiple sclerosis (Fig-
ure 5) may simply be to reduce expression levels (Swaminathan
et al., 2013). Reduced expression levels will lower both the
threshold of activation and ligand engagement (Hassan et al.,
2006). The strongest association of a SNP in CD6 with disease
susceptibility is in an intron, and correlates with a reduced ratio
of expression of full-length CD6 compared with a form of CD6
which lacks the ligand binding domain, suggesting that the
dominant effect is mediated by decreased ligand binding (Castro
et al., 2007; Kofler et al., 2011). Disease association for the less
commonSNP, S351N, which has reduced affinity for CD166, has
not yet been reported. Mutagenesis and mass spectrometric
analysis provided evidence that reduced binding was due to
glycosylation of CD6 at S351N. We assume this high frequency
SNP is likely to be associated with subtle functional changes in
CD6 activity.
Topology of CD6/CD166 Interactions
On engagement by CD166, CD6 has been observed tomove into
areas of close contact between T cells and antigen-presenting
cells (Castro et al., 2007; Gimferrer et al., 2004; Zimmerman
et al., 2006), suggesting that the interacting receptors will match
the dimensions of the T-cell receptor and other receptors
observed to colocalize, 140 A˚ (Dushek et al., 2012) (Figure 2).
The nonlinear domain structure may be important for accommo-
dating CD6 in areas of close apposition between cells. The
nonlinear structure of the three SRCR domains spans 78.1 A˚.
This excludes the 37 amino acidmembrane proximal stalk region
of unknown dimensions. The two IgSF V domains of CD166
span 90.4 A˚, comparable with the dimensions of the two IgSF
V domains in another cell surface receptor, JAM (86 A˚, PDB:
1F97). Extrapolating from the dimensions of the two CD166
IgSF V and three C domains taking the size of a C domain to
Table 2. CalculatedMass Species of CD6 and CD166 from Native
Mass Spectrometry
Experimentally
Calculated Mass (Da) Standard Deviation (Da)
CD6
Monomer 1 44,509 ±3
Monomer 2 45,721 ±4
Dimer 1 89,135 ±13
Dimer 2 90,173 ±16
Dimer 3 91,436 ±13
CD166
Monomer 1 39,751 ±8
Monomer 2 40,139 ±12
Monomer 3 40,975 ±4
Monomer 4 41,198 ±6
Dimer 1 80,045 ±9
Dimer 2 81,046 ±24
Dimer 3 82,112 ±24
CD6/CD166
Dimer 1 84,557 ±40
Dimer 2 85,592 ±32
Dimer 3 86,770 ±24
Figure 7. Heterodimers Are Formed at the Expense of CD6 and
CD166 Homodimers
Native mass spectrometry data are shown for the CD6 (A) and CD166 (B)
proteins separately, and for the CD6/CD166 mixture (C). The CD6 and CD166
proteins exist predominantly in a monomer-dimer equilibrium. Charge state
series are indicated with circles: gray and red for CD6 monomer and dimer;
and black and green for CD166 monomer and dimer, respectively. In the
mixture (C), the CD6/CD166 heterodimer, indicated with blue circles, is the
most abundant species. Smaller amounts of individual CD6 and CD166
monomers, colored in cyan, also exist. Where more than one mass was found
for a species due to glycosylation, only the most abundant one is indicated on
the spectra for clarity. All experimentally calculated masses can be found in
Table 2.be 35 A˚ from human CD2 domain 2 (PDB: 1HNG), the five do-
mains in a linear array would be predicted to span 200 A˚.
This suggests there is flexibility and/or deviation from the
perpendicular by CD166 between apposing cells to optimize
formation of trans interactions, as has been proposed for five
domain E-cadherins (Wu et al., 2011). If the parallel, as distinct
from anti-parallel orientation of the interacting CD166 N-terminal
domains, is physiological, it will restrict the dimensions of homo-
philic trans interactions (Te Riet et al., 2014; van Kempen et al.,
2001). Determination of the X-ray crystal structures of CD6 and
CD166 allows us to create a more accurate model of how these
proteins regulate interactions at the cell surface, and to design
the most effective therapeutic reagents.EXPERIMENTAL PROCEDURES
Recombinant Proteins for Crystallization
Three human CD6 (GenBank: U34623; UniProt: P30203) SRCR domains (res-
idues 1–364) and two V-like domains and one C-like domain (VVC) (residues
1–335) of human CD166 (UniProt: Q13740) were amplified from plasmid
DNA (Bowen et al., 1996) and expressed as endoglycosidase H sensitive
His-tagged proteins (CD6; LCSASRGHHHHHH CD166; YLDLSTRHHHHHH)
containing their native leader sequences using PEE14 vector in CHO Lec
3.2.8.1 cells (Chen and Stanley, 2003). CHO cell lines selected for stable
expression were grown in cell factories to confluence; sodium butyrate
(2 mM) was then added and the cells were allowed to secrete for 2–3 weeks
before harvesting. Tissue culture supernatant was concentrated (Sartorius
Vivablock, molecular weight cutoff 10 kDa) and proteins purified using nickel
chromatography columns (NiNTA, Qiagen) and elution with an imidazole
gradient in 10 mM HEPES, 150 mM NaCl (pH 7.4). Proteins were immediately
dialyzed to remove imidazole and then subjected to size-exclusion chromatog-
raphy (Superdex200 column; GEHealthcare). For crystallization, proteins were
deglycosylated with EndoHf (New England Biolabs), 0.3–2.5 U/ml in 10 mM
HEPES, 150 mM NaCl (pH 7.4) at 37C for 2 hr and analyzed by SDS-PAGE.
Crystallization
The three extracellular SRCR domains of human CD6 were crystallized using
the sitting drop method in 0.1 M ammonium sulfate, 0.3 M sodium formate,
0.1M sodium cacodylate, 3%w/v PGA-LM, 20%MPD (pH 6.5) at 20C. Drops
were set up using 2.5 ml of a protein solution containing a complex of CD6 and
CD166 at an OD280 of 2.22, and 2.5 ml of the reservoir solution. CD6 crystals
grew within 4 weeks.
The two membrane distal immunoglobulin domains of human CD166 were
crystallized using the sitting drop method in 0.1 M sodium HEPES (pH 7.5)
and 25% w/v PEG-2000 MME. Drops were set up using 2 ml of a protein solu-
tion containing CD166 domains 1–3 at an OD280 of 4.58. Crystals grew after
4 weeks. Crystals were flash-frozen in liquid nitrogen and data were collected
at the Diamond Light Source, Harwell, at 100 K on beamline i04-1.
Data Collection and Processing
Native datasets were collected for CD6 and CD166, to 3.15 A˚ and 1.86 A˚,
respectively. The data were integrated and scaled using XDS (Kabsch, 2010)Structure 23, 1426–1436, August 4, 2015 ª2015 The Authors 1433
and aimless (Evans and Murshudov, 2013) as implemented in XIA2 (Winter
et al., 2013). Molecular replacement search models were generated using
CHAINSAW (Stein, 2008), and large loops removed. The structure of human
CD6 was solved by searching for three copies of a search model derived
from the Mac2 binding protein, a single SRCR domain (PDB: 1BY2; Ho-
henester et al., 1999) using PHASER (McCoy et al., 2007), part of the CCP4
software suite (Winn et al., 2011). The human CD166 structure was solved
by searching with a search model derived from the second immunoglobulin
domain in the ligand binding domain of human RAGE (PDB: 3CJJ; Koch
et al., 2010). Model building and refinement were carried out using Coot (Ems-
ley et al., 2010) and AUTOBUSTER (Bricogne et al., 2011). The CD6 andCD166
structures were refined to Rwork/Rfree of 0.25/0.28 and 0.22/0.24, respectively.
Coordinates were deposited in the PDB (PDB: 5a2e for CD6 and PDB: 5a2f for
CD166).
Native Mass Spectrometry
Purified CD6 and CD166, along with a mixture of both proteins, were sub-
jected to native mass spectrometry analysis. Proteins were at a concentra-
tion of 20 mM and the mixture formed by incubating an equal amount of
CD6 and CD166 (both at 20 mM) for 30 min at room temperature. Samples
were buffer exchanged from 10 mM HEPES, 150 mM NaCl (pH 7.4) into
250 mM ammonium acetate (pH 7.6) using Biospin-6 columns (Bio-Rad).
Mass spectrometry measurements were carried out on a modified Synapt
G1 HDMS (Waters Corp.) Q-ToF mass spectrometer (Bush et al., 2010).
The instrument was mass calibrated using a solution of 10 mg/ml cesium
iodide in water. Aliquots (2 ml) of samples were delivered to the mass spec-
trometer by means of nano-electrospray ionization via gold-coated capil-
laries, prepared in-house (Hernandez and Robinson, 2007). Instrumental
parameters were as follows: source pressure 5.6 mbar, capillary voltage
1.20 kV, cone voltage 50 V, trap energy 10 V, bias voltage 5 V, and trap pres-
sure 1.63 3 102 mbar. The trap energy was increased to 30 V to obtain
more accurate mass measurements.
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